- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: CH 5132799 | CH-5132799 | CH5132799 | MEN-1611 | MEN1611
Compound class: Synthetic organic
Comment: Izorlisib (MEN1611 and formerly CH5132799) is described as a potent, orally available class I PI3K inhibitor . Clinical development of CH5132799 has been licenced to Menarini Pharma from Chugai Pharmaceutical Co, hence the change in research code.
The chemical structure of MEN1611 is identical to that which was submitted to the WHO for the INN izorlisib (proposed INN list 126, Jan 2022).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|International Nonproprietary Names
|CH 5132799 | CH-5132799 | CH5132799 | MEN-1611 | MEN1611
|CAS Registry No.
|GtoPdb PubChem SID
|RCSB PDB Ligand
|Search Google for chemical match using the InChIKey
|Search Google for chemicals with the same backbone
|Search PubMed clinical trials
|Search PubMed titles
|Search PubMed titles/abstracts
|80292 (in complex with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma)
|UniChem Compound Search for chemical match using the InChIKey
|UniChem Connectivity Search for chemical match using the InChIKey